Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Power wheelchair fraud rolled back

This article was originally published in The Gray Sheet

Executive Summary

Unpaid Medicare claim rate is 98.4% for power wheelchairs in Harris County, Texas over the past year, wheelchair distributor The Scooter Store says. CMS' anti-fraud campaign, "Operation Wheeler Dealer," launched in September 2003, singled out Harris County as an area where potential billing fraud appeared "most egregious" and required CMS staff to personally signoff on payments for claims in the region (1"The Gray Sheet" Sept. 15, 2003, p. 4). Medicare paid for more than 31,000 power chairs in 2002 in Harris County, over 10 times the 2001 total of 3,000. TSS charges that the "sharply restrictive" claims review process for Harris represents "geographical discrimination." The firm notes a 95% approval rate for its Medicare power wheelchair claims nationwide...

You may also be interested in...



Power Wheelchairs Targeted For Inherent Reasonableness Price Adjustments

CMS plans to develop inherent reasonableness review guidelines to ensure appropriate Medicare payments for motorized wheelchairs as part of a larger initiative to curb provider billing fraud, the agency says

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021218

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel